Personalized vaccine for ovarian cancer that did not fully respond
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) that are trained to recognize specific markers on your ovarian cancer. The goal is to see if this vaccine is safe and helps your immune system fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 to 70, weighing at least 45 kg.
- You must have ovarian cancer that did not fully respond to your first treatment (surgery plus platinum-based chemotherapy). Your CA125 levels may be abnormal or you may have a visible tumor that can be measured.
- You must have had genetic testing on your tumor to identify specific markers (neoantigens) that will be used to create your own personalized vaccine.
- Your blood counts and organ function (like liver and kidney) must be within certain limits, which will be checked with blood tests.
- You must have recovered from side effects of previous treatments, and you must be able to undergo a procedure to collect your white blood cells.
- You must agree to use effective birth control during the trial and for 6 months after your last dose of the study treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized cancer vaccine made from your own tumor cells. It is for women with advanced ovarian, fallopian tube, or primary peritoneal cancer that has returned after at least one round of platinum chemotherapy.
This trial tests a personalized vaccine made from your tumor's genetic material. It is given after surgery to help your immune system recognize and attack any remaining cancer cells, with the goal of preventing the cancer from coming back.
This trial tests a personalized vaccine for people with epithelial ovarian cancer who still have a small amount of cancer DNA in their blood after surgery. The goal is to see if the vaccine can help stop the cancer from coming back.
This trial tests a personalized vaccine made from your own tumor tissue called NeoOVSV. It is meant to train your immune system to fight any remaining cancer after surgery. The vaccine is a personal treatment because it uses your tumor's unique markers.
This trial tests a personalized vaccine made from your tumor's unique proteins to help your immune system fight high-risk or advanced endometrial cancer. It is given along with your regular cancer treatments.
This trial tests a personalized vaccine (ODI-2001) that is made from your own tumor. It is given during a break from chemotherapy to see if it is safe and can help keep the cancer from growing.
Hear when a new HRD-negative Epithelial Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.